Anuh Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
ANUHPHR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.2 pts less than Nifty Microcap 250 and 6.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Anuh Pharma reported FY2026 revenue of Rs. 77,166 Lakhs, up 16.6% from Rs. 66,151 Lakhs in FY2025, driven by higher volumes in bulk drugs and chemicals. However, profit after tax declined 13.3% to Rs. 4,105 Lakhs from Rs. 4,735 Lakhs, impacted by rising raw material costs and unfavorable forex movements. EBITDA margin compressed to 8.56% from 10.64% in the prior year. The company declared a dividend of Rs. 1.50 per share (30% payout) subject to shareholder approval. A 1:1 bonus issue was completed in July 2025, doubling the equity share capital to Rs. 5,011 Lakhs. The audit opinion remains unmodified with no qualifications. Nine promoter group shareholders (holding 0.95% stake) have sought reclassification to public category.
Revenue growth of 16.6% shows solid business expansion, but the 13.3% PAT decline and EBITDA margin compression of over 2 percentage points signal cost pressures that may concern investors. The clean audit and dividend declaration provide some support. The promoter reclassification request is minor at under 1% stake.